

Structural determinants of arylacetic acid NSAIDs necessary for binding and activation of the PGD₂ receptor CRTH2

Aaron N. Hata, Terry P. Lybrand, Lawrence J. Marnett and Richard M. Breyer

Department of Pharmacology (ANH, TPL, RMB), Department of Medicine (ANH, RMB), Department of Chemistry (TPL), Vanderbilt Center for Structural Biology (TPL), Department of Biochemistry (LJM), Vanderbilt-Ingram Cancer Center (LJM, RMB), and Vanderbilt Institute of Chemical Biology (LJM), Vanderbilt University School of Medicine, Nashville, TN 37232

Running Title: Interaction of NSAIDs with the mouse CRTH2 receptor

Address correspondence to:

Richard M. Breyer, Vanderbilt University School of Medicine, Division of Nephrology, S3223
MCN, 1161 21st Ave South, Nashville, TN 37232-2372, (Tel) 615-343-0257, (Fax) 615-343-
4704, (Email) rich.breyer@vanderbilt.edu

Text pages: 30

Figures: 6

References: 40

Word Counts: Abstract, 250; Introduction, 578; Discussion, 1471

Abbreviations:

[cAMP] _i	Intracellular cyclic AMP
CRTH2	Chemoattractant receptor-homologous molecule expressed on Th2 cells
2-DMI	2-desmethyl indomethacin
5'-DMI	5'- <i>O</i> -desmethyl indomethacin
GPCR	G protein-coupled receptor
5-HIAA	5-hydroxy indole acetic acid
NSAID	Nonsteroidal antiinflammatory drug
PBI	<i>p</i> -bromobenzyl indomethacin
PPAR	Peroxisome proliferator-activated receptor
IBMX	3-isobutyl-1-methylxanthine

Abstract

The CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells) receptor, a G protein-coupled receptor that mediates chemotaxis of inflammatory cells in response to PGD₂, is hypothesized to play a role in Th2-mediated allergic disease. In addition to PGD₂, CRTH2 can be activated by indomethacin, a non-selective cyclooxygenase inhibitor and widely used nonsteroidal antiinflammatory drug (NSAID). To evaluate the structural features that confer CRTH2 binding selectivity, structure-activity relationship analysis of arylacetic acid-class NSAIDs as CRTH2 receptor ligands was performed. Indomethacin, sulindac sulfide and zomepirac displaced [³H]PGD₂ binding at the mouse CRTH2 receptor with comparable affinity ($K_i = 1.5 \pm 0.1$, 2.5 ± 0.4 and 3.3 ± 0.3 μM , respectively). The indomethacin metabolite 5'-*O*-desmethyl indomethacin (5'-DMI) possessed binding affinity similar to indomethacin, however elimination of the 2-methyl substituent on the indole ring resulted in a 10-fold decrease in binding affinity. No binding was detected for indole acetic acid and indole derivatives such as tryptophan, serotonin and 5-HIAA, demonstrating the importance of the *N*-acyl moiety of indomethacin. Neutral derivatives of indomethacin also failed to bind to mCRTH2, suggesting that the negatively-charged carboxylate moiety participates in a key ligand-receptor interaction. Despite similar binding affinities, NSAID-type mCRTH2 ligands exhibited variable potencies as mCRTH2 agonists. Sulindac sulfide and 5'-DMI inhibited [cAMP]_i generation and stimulated cell migration comparable to indomethacin. In contrast, zomepirac did not inhibit [cAMP]_i generation or stimulate cell migration but weakly antagonized the effects of indomethacin on [cAMP]_i. Taken together, these results reveal structural features of arylacetic acid NSAIDs that may be exploited for the development of selective CRTH2 ligands.

Introduction

Prostaglandin D₂ (PGD₂), the predominant prostanoid produced by activated mast cells is associated with allergic diseases such as allergic asthma and atopic dermatitis (Barr et al., 1988; Lewis et al., 1982; Murray et al., 1986). The biological effects of PGD₂ are mediated by two distinct G protein-coupled receptors (GPCRs)—the D prostanoid receptor (DP) and the recently discovered chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). Despite binding PGD₂ with high affinity, the CRTH2 receptor does not share significant sequence homology with the DP or other prostanoid receptors; instead, it exhibits greatest sequence similarity to chemoattractant receptors such as the formyl peptide receptor (Hirai et al., 2001). In humans, the CRTH2 receptor is expressed on Th2 cells and eosinophils (Nagata et al., 1999a; Nagata et al., 1999b) which are well known to play a role in the pathogenesis of allergic diseases such as allergic asthma (Hamid et al., 2003). *In vitro* activation of CRTH2 stimulates chemotaxis of human Th2 cells, eosinophils and basophils and *in vivo* activation leads to leukocyte mobilization in rats (Hirai et al., 2001; Shichijo et al., 2003), suggesting that CRTH2 may mediate recruitment of inflammatory cells in response to PGD₂ generated in the setting of allergic inflammation.

Although the precise role of CRTH2 in allergic disease has yet to be fully elucidated, emerging data suggest that it may mediate pro-inflammatory effects of PGD₂. Therefore, the generation of selective and specific CRTH2 antagonists is of interest as potential therapeutic agents for the treatment of allergic disease. Recently it was reported that ramatroban, initially described as a thromboxane receptor (TP) antagonist and marketed for allergic rhinitis in Japan, has significant CRTH2 antagonist activity and can inhibit PGD₂-stimulated eosinophil migration *in vitro* (Sugimoto et al., 2003). Consistent with this finding, ramatroban was observed to inhibit

antigen-induced mucosal eosinophilia in sensitized guinea pigs (Narita et al., 1996), an effect unlikely to be due to direct inhibition of TP receptors on eosinophils. Currently, however, no truly CRTH2-selective antagonist has been reported.

Indomethacin is an arylacetic acid class non-selective cyclooxygenase (COX) inhibitor and widely prescribed nonsteroidal antiinflammatory drug (NSAID). In addition to suppressing prostaglandin formation by inhibiting COX, indomethacin is known to possess COX-independent activity such as suppression of malignant transformation of embryonic fibroblasts (Zhang et al., 1999) and activation of the peroxisome proliferator-activated receptors α and γ (Lehmann et al., 1997). Indomethacin has also been shown to be an agonist at the CRTH2 receptor and to stimulate shape change, CD11b up-regulation and chemotaxis of eosinophils (Hirai et al., 2002; Stubbs et al., 2002). This novel activity of indomethacin is not shared by other NSAIDs such as aspirin or ibuprofen. We have reported that indomethacin and sulindac, also an arylacetic acid NSAID, can bind to the mouse CRTH2 receptor (mCRTH2), suggesting that arylacetic acid class NSAIDs possess a unique structural motif that allows binding to CRTH2 (Hata et al., 2003). Whereas the structure-activity relationships of indomethacin derivatives as selective inhibitors of the cyclooxygenase isozymes have been extensively studied (Kalgutkar et al., 2000a; Kalgutkar et al., 2000b), little is known about these molecules as CRTH2 ligands. Based on our initial observations, we hypothesized that the arylacetic acid core provides a fundamental structural motif that allows this class of NSAIDs to bind and activate the CRTH2 receptor. To define the structural features required for the novel CRTH2 activity of arylacetic acid NSAIDs, we performed structure-activity relationship analysis on a series of arylacetic acid NSAIDs and indomethacin derivatives as mCRTH2 agonists.

Materials and Methods

Reagents

Indomethacin [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid], NSAIDs, indole derivatives, forskolin and IBMX were from Sigma (St. Louis, MO). Indomethacin derivatives were synthesized as previously described (Kalgutkar et al., 2000b; Prusakiewicz et al., 2004). 5'-*O*-desmethyl indomethacin (5'-DMI) was obtained from Merck Pharmaceuticals (West Point, PA). Ramatroban [(+)-(3R)-3-(4-fluorobenzenesulfonamido)-1,2,3,4-tetrahydrocarba-zole-9-proprionic acid] was obtained from Bayer AG, (Kyoto, Japan). [³H]PGD₂ was purchased from Amersham Biosciences (Piscataway, NJ). DMEM and Opti-MEM were from Invitrogen (Carlsbad, CA). FBS was obtained from Atlanta Biologicals (Lawrenceville, GA). G418 was purchased from Mediatech (Herndon, VA). L-glutamine and penicillin/streptomycin were from BioWhittaker (Walkersville, MD). Ponasterone A was purchased from Stratagene (La Jolla, CA).

Expression of CRTH2 in HEK293 and ER293 cells

Transient expression of mCRTH2 in HEK293 cells and generation of the ER293/mCRTH2 cell line has been described previously (Hata et al., 2003). The human CRTH2 receptor (hCRTH2) expression plasmid was obtained from the Guthrie cDNA Resource Center (Sayre, PA) and transiently transfected into HEK293 cells in a similar manner. Cells were maintained at 37°C in humidified air containing 5.5% CO₂ in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 units ml⁻¹ penicillin, 100 µg ml⁻¹ streptomycin. Media for ER293

cells was additionally supplemented with 300 $\mu\text{g/ml}$ G418 and 100 $\mu\text{g/ml}$ hygromycin B. Expression of mCRTH2 in ER293/mCRTH2 cells was induced by addition of 10 μM ponasterone A 24 hours prior to all experiments.

Radioligand binding assay

HEK293/mCRTH2 and HEK293/hCRTH2 membranes for radioligand binding experiments were harvested as described (Hata et al., 2003). Membranes (30 μg membrane protein) were incubated with [^3H]PGD₂ at 4°C for 1.5 hours in binding buffer (25 mM HEPES (pH7.4), 1 mM EDTA, 5 mM MgCl₂, 140 mM NaCl, 5 mM KCl). The binding reaction was terminated by the addition of 3 ml ice-cold binding buffer and rapidly filtered under vacuum over Whatman GF/F filters. Filters were washed three times with 3 ml ice-cold binding buffer, dried and counted in 4 ml Ultima Gold scintillation fluid (Packard Biosciences, Groningen, The Netherlands).

[cAMP]_i assay

ER293/mCRTH2 cells were grown to 80% confluence in 6-well plates and incubated for 24 hours in the presence of 10 μM ponasterone A. Thirty minutes prior to addition of ligands, media was replaced with Opti-MEM I containing 0.5 mM IBMX. Cells were incubated with ligands for 10 minutes, washed once with PBS, and the reaction was terminated by the addition of 0.1 M HCl. Cells were scraped free and the resulting cell suspension was centrifuged for 10 minutes at 1000 x g. Supernatants were assayed for protein content by BCA assay (Pierce, Rockford, IL). After normalization to protein content, [cAMP]_i levels were determined by an enzyme-linked immunoassay according to the manufacturer's instructions (Cayman Chemical).

Cell migration assay

ER293/mCRTH2 cells were incubated with 10 μ M ponasterone A for 24 hours prior to harvesting. Cells were trypsinized, washed three times in PBS and resuspended in DMEM. Cells (100,000) were added to the upper chamber of 24-well 8.0 μ m polycarbonate transwell inserts (Costar, Cambridge, MA) that had been previously treated overnight with 5 μ g/ml Matrigel (BD Biosciences, Bedford, MA) in PBS at 4°C and blocked in the presence of 2% BSA in PBS for one hour at 37°C. Ligands were diluted in DMEM and added to the lower chamber. After incubating for 4 hours at 37°C, inserts were removed and cells adhering to the top of the membrane were removed with a cotton swab. Cells on the bottom of the membrane were fixed with 3.7% formaldehyde for one hour, washed twice with PBS and stained overnight with crystal violet. For each insert, five independent fields were counted in blinded fashion at 200x magnification.

Cyclooxygenase activity assay

Time-dependent inhibition of ovine cyclooxygenase-1 and murine cyclooxygenase-2 was measured as previously described (Kalgutkar et al., 2000b).

Molecular modeling of mCRTH2

The transmembrane spanning alpha-helical bundle of mCRTH2 was constructed with homology modeling methods, using a current β_2 -adrenergic receptor model as a template (Furse and Lybrand, 2003). Amino acid side chains in the β_2 -adrenergic receptor model were replaced to generate the mCRTH2 sequence, using a backbone-dependent side chain rotamer library.

Limited energy minimization was used to relieve unfavorable steric interactions after side chain replacement. The extracellular and cytosolic loops were generated *de novo*. The amino and carboxy terminal segments of each loop were constructed as extended peptides, and attached to the end of the appropriate transmembrane helix. Weak harmonic constraints were then applied gradually during short (10-20ps), low-temperature (30K) molecular dynamics simulations to connect appropriate loop segments with a trans peptide bond. A putative disulfide crosslink between the extracellular region of transmembrane helix III and extracellular loop 2 was generated by applying additional constraints during the generation of extracellular loop 2. To simplify model construction, the C-terminal tail was truncated at V321. The intact mCRTH2 receptor model was then refined further with limited energy minimization and low-temperature molecular dynamics simulation to relieve any peptide backbone conformational strain or residual bad steric interactions. Indomethacin was then docked into the putative ligand binding pocket using an automated ligand docking algorithm. All structural refinement calculations were performed *in vacuo* with a distance-dependent dielectric model, using standard AMBER all-atom potential functions. Energy minimization and molecular dynamics calculations were performed with the AMBER package. Ligand docking was performed using the automated docking module in MOE (Chemical Computing, Inc.).

Data analysis

All data are presented as the mean \pm S.E.M. Competition binding curves and IC_{50} values were calculated using a one-site competition model (Prism 4, GraphPad). K_i values were calculated according to the method of Cheng and Prusoff (Cheng and Prusoff, 1973). EC_{50} values for [cAMP]_i dose-response experiments were calculated using a fixed slope sigmoidal

dose-response model (Prism). Differences between means were tested for statistical significance using two-tailed unpaired t-test for $[cAMP]_i$ and chemotaxis experiments, with $p < 0.05$ considered significant (InStat 3, GraphPad).

Results

A panel of NSAIDs was screened for their ability to displace [^3H]PGD₂ from the mouse CRTH2 receptor expressed in HEK293 cells. In addition to indomethacin and sulindac (Hata et al., 2003), the arylacetic acid sulindac sulfide and zomepirac also displaced [^3H]PGD₂ binding with high affinity ($K_i = 1.5 \pm 0.1$, 2.5 ± 0.4 and 3.3 ± 0.3 μM for indomethacin, sulindac sulfide and zomepirac, respectively); in contrast, diclofenac did not display detectable binding (Figure 1). The binding of indomethacin to the human CRTH2 receptor (hCRTH2) has been previously characterized (Hirai et al., 2002; Sawyer et al., 2002); our binding assays confirmed that the affinity of indomethacin for hCRTH2 ($K_i = 3 \pm 1$ μM ; data not shown) is similar to the affinity reported by Hirai and coworkers and similar to that of the mouse ortholog.

The arylacetic acid core of indomethacin is analogous to indole-3-acetic acid (IAA), a plant auxin that modulates a number of growth processes (Goldsmith, 1993). In addition to IAA, several other biologically active molecules share an indole or IAA core, most notably serotonin and its immediate precursors and metabolites (Figure 2). To investigate the importance of the IAA core in conferring affinity for mCRTH2, we tested whether these molecules were capable of binding to mCRTH2. These compounds were unable to displace [^3H]PGD₂ at concentrations up to 30 μM (Figure 3a). Thus, the IAA core of indomethacin and other arylacetic acid NSAIDs is not in itself sufficient to confer binding to mCRTH2.

In vivo, indomethacin undergoes demethylation of the 5'-O-desmethyl substituent to yield 5'-DMI, which has been reported to lack anti-inflammatory properties (Shen, 1964; Van Dyke et al., 1982). In contrast, 5'-DMI exhibited comparable mCRTH2 binding affinity ($K_i = 3.9 \pm 1.2$ μM) to indomethacin (Figure 3b). Removal of the 2-methyl substituent (2-desmethyl indomethacin; 2-DMI) resulted in a 10-fold decrease in binding affinity ($K_i = 15 \pm 4$ μM). Thus,

the 2-methyl but not the 5'-*O*-methyl substituent contributes to the CRTH2 binding affinity of indomethacin (Figure 3b). In addition, indomethacin possesses a *p*-substituted *N*-acyl moiety, a structural feature that is present in sulindac sulfide and zomepirac. Comparison of the binding affinities for 2-DMI and 5-HIAA, which differ principally in the absence or presence of the *N*-acyl moiety, strongly suggests that this substituent is essential for high affinity binding to mCRTH2. The *p*-bromobenzyl indomethacin derivative (PBI) also bound to mCRTH2 with similar affinity as indomethacin ($K_i = 1.2 \pm 0.3 \mu\text{M}$).

To investigate the role that the carboxylate group plays in indomethacin-CRTH2 interaction, we assessed the ability of the primary amide and methyl ester derivatives of indomethacin to bind to mCRTH2. Neither the methyl ester nor primary amide derivative showed significant binding to mCRTH2 at concentrations up to 30 μM (Figure 3c), indicating that the carboxyl moiety is critical for binding.

Ramatroban was recently reported to be a CRTH2 antagonist (Sugimoto et al., 2003) and shares structural similarity with arylacetic acid NSAIDs (Figure 2). Ramatroban displaced [^3H]PGD₂ binding with high affinity in our binding assays ($K_i = 28 \pm 6 \text{ nM}$; data not shown), which is in good agreement with the reported K_i values of $47 \pm 13 \text{ nM}$ and $60 \pm 13 \text{ nM}$ for human and mouse CRTH2 receptors expressed in L1.2 mouse B cell leukemia cells (Shichijo et al., 2003).

We next investigated the agonist activity of compounds having significant binding activity at mCRTH2 in [cAMP]_i inhibition and chemotaxis assays. Indomethacin, 5'-DMI and PBI (1 μM) fully activated mCRTH2 leading to inhibition of [cAMP]_i generation in ER293/mCRTH2 cells as demonstrated by a maximal inhibitory effect equivalent to that of the endogenous agonist PGD₂ (Figure 4a). Sulindac sulfide was also capable of achieving a

maximal inhibitory effect at higher concentrations (10 μ M; data not shown). Similar to the rank order of relative binding affinities, 5'-DMI exhibited similar potency as indomethacin ($IC_{50} = 7 \pm 3$ nM and 2.5 ± 0.9 nM, respectively) while 2-DMI was 20-fold less potent ($IC_{50} = 50 \pm 20$ nM; Figure 4b). In contrast, concentrations of zomepirac up to 50 μ M did not significantly decrease $[cAMP]_i$ levels (Figure 4c) despite its similar binding affinity to indomethacin. To determine whether zomepirac is a mCRTH2 antagonist, we evaluated whether it was capable of antagonizing indomethacin-induced inhibition of $[cAMP]_i$. At high concentrations, zomepirac partially antagonized the effects of indomethacin (Figure 4d), whereas the CRTH2 antagonist ramatroban fully reversed the indomethacin-induced inhibition of $[cAMP]_i$ (ramatroban $IC_{50} = 120 \pm 50$ nM; data not shown). Consistent with their ability to act as mCRTH2 agonists and inhibit $[cAMP]_i$, indomethacin, PBI, 5'-DMI, 2-DMI and sulindac sulfide but not zomepirac (100 nM) stimulated migration of mCRTH2-transfected ER293 cells (Figure 5).

To confirm previous reports that 5'-DMI lacks COX inhibitory activity (Shen, 1964; Van Dyke et al., 1982), we tested 5'-DMI for its ability to directly inhibit COX-1 and -2 *in vitro*. Surprisingly, 5'-DMI showed identical inhibition of mouse COX-2 compared to indomethacin ($IC_{50} = 250$ nM for both) and slightly lower activity in inhibiting sheep COX-1 ($IC_{50} = 210$ and 35 nM, respectively).

To visualize potential ligand-receptor interactions, we modeled the mCRTH2 receptor using a combination of *de novo* and homology modeling techniques starting from the transmembrane helical bundle of a previously described model of the β_2 -adrenergic receptor (Furse and Lybrand, 2003). Similar to other small-molecule binding GPCRs, the putative ligand binding pocket is located within the top (extracellular) third of the transmembrane helical bundle (Figure 6a). Ligand docking simulations yielded several different low energy conformations for

indomethacin within the ligand binding pocket. Interestingly, in one low energy indomethacin-mCRTH2 complex, the acetate carboxylate of indomethacin forms a charge stabilized hydrogen bond with K209 in helix V (Figure 6b) and the *p*-chlorobenzoyl moiety is positioned to form hydrophobic stacking interactions with the aromatic ring of F110 in helix III (Figure 6c).

Discussion

Although indomethacin is predominantly known as a non-selective COX inhibitor, it has been shown to elicit a number of COX-independent effects including activation of PPAR γ leading to adipocyte differentiation (Lehmann et al., 1997), inhibition of malignant transformation of embryonic fibroblasts (Zhang et al., 1999) and inhibition of the PGD₂ 11-ketoreductase AKR1C3 (Lovering et al., 2004). It has also been demonstrated to stimulate eosinophil shape change, CD11b expression and chemotaxis via direct activation of the CRTH2 receptor (Hirai et al., 2002; Stubbs et al., 2002). Hirai and others have reported that indomethacin, but not other NSAIDs such as aspirin and ibuprofen, is an agonist at the human CRTH2 receptor (Hirai et al., 2002; Stubbs et al., 2002), and we confirmed that the mouse CRTH2 ortholog shares a similar pharmacological profile (Hata et al., 2003). The reported binding affinity constants (K_i) for indomethacin at the human CRTH2 receptor vary from 25 nM (Sawyer et al., 2002) to 8 μ M (Hirai et al., 2002). The reason for this discrepancy is unclear, however the assay conditions employed in the present binding studies support affinities for indomethacin at both human and mouse CRTH2 receptors in the low micromolar range. The K_i value for sulindac sulfide at hCRTH2 has also been reported (3.5 μ M; Sawyer et al., 2002), and is similar to the value of 2.5 μ M for mCRTH2.

Although the structure-activity relationships of arylacetic acid NSAIDs as selective and non-selective COX inhibitors have been characterized (Kalgutkar et al., 2000b), little is known about the structural determinants necessary for CRTH2 binding. No binding was observed for compounds that included only the indole or indole-acetic acid core, suggesting that the arylacetic acid core alone is not sufficient for binding. On the other hand, the presence of the *p*-substituted *N*-acyl moiety appeared to correlate with mCRTH2 binding affinity. For instance, both 5'-DMI

and 2-DMI bind to mCRTH2 with micromolar affinity, whereas 5-HIAA, which differs principally in the absence of this moiety, showed no significant binding at concentrations tested. Zomepirac, which lacks the indole acetic acid core but possesses the identical *N*-(*p*-chlorobenzoyl) group to indomethacin, binds with similar affinity to indomethacin. Our molecular modeling studies suggest that this moiety could form hydrophobic interactions with the aromatic ring of F110 of helix III. Beyond the apparent requirement for the *p*-substituted *N*-acyl moiety, the ligand binding pocket of mCRTH2 tolerates slight variations in substituent size at the *para* position as demonstrated by the fact that sulindac sulfide and PBI have similar binding affinities. Binding studies also revealed that the 2-methyl substituent of indomethacin plays a role, albeit less important, in mCRTH2 binding. 2-DMI possesses a 10-fold lower affinity for mCRTH2 compared to indomethacin, and a similar relative difference was observed in ability to inhibit FSK-stimulated [cAMP]_i.

Interactions between the negatively-charged carboxylate moiety of a ligand and positively-charged residues within the ligand binding pocket have been implicated in ligand binding and activation of prostanoid (Audoly and Breyer, 1997; Negishi et al., 1995) and chemoattractant receptors (DeMartino et al., 1995; Mills et al., 2000). Neutralization of the indomethacin carboxylate moiety by derivatization to the methyl ester or primary amide form abolished mCRTH2 binding. By comparison, neutralization of the carboxylate moiety of indomethacin decreases COX-1 but slightly increases COX-2 inhibitory activity, leading to a substantial enhancement of COX-2 selectivity (Kalgutkar et al., 2000b). Although the potential impact of subtle volume differences between the indomethacin free acid and neutral derivatives cannot be ignored, it is likely that the decrease in binding affinity is due to the loss of the negative charge and potential disruption of an interaction with a positively-charged residue

sidechain within the binding pocket. The primary structure of mCRTH2 reveals several positively-charged residues that may be candidates for this interaction including K209 in TMV which is analogous to R205 in the formyl peptide receptor and R206 in the C5a receptor, both of which have been demonstrated to interact with ligand (DeMartino et al., 1995; Mills et al., 2000). Our molecular modeling studies support this possibility and suggest the presence of a charge-stabilized hydrogen bond between K209 and the indomethacin carboxylate.

In most instances, the arylacetic acid NSAIDs and indomethacin derivatives functioned as full mCRTH2 agonists and inhibited $[cAMP]_i$ and stimulated cell migration to a similar magnitude as the endogenous ligand PGD_2 . However, zomepirac failed to inhibit $[cAMP]_i$ even at high ligand concentrations where >90% of the receptor would be expected to be occupied by ligand (i.e. 50 μM). On the other hand, zomepirac weakly antagonized the ability of indomethacin to inhibit $[cAMP]_i$ at high concentrations, raising the possibility that this class of molecules may be exploited for the development of CRTH2 antagonists. Ramatroban, the only CRTH2 antagonist reported to date, shares structural similarity with indomethacin including a negatively charged carboxylate and a *p*-substituted acyl moiety. It is worth noting that indomethacin and its desmethyl derivatives are capable of activating mCRTH2 at nanomolar concentrations despite having micromolar binding affinities ($EC_{50,(cAMP)}$ and K_i for indomethacin are 2.5 nM and 1.5 μM , respectively) whereas the difference between EC_{50} and K_i for PGD_2 is much smaller ($EC_{50,(cAMP)}$ and $K_i = 0.9$ nM and 38 nM, respectively; Hata et al., 2003). A similar phenomenon has been reported for the human CRTH2 ortholog whereby indomethacin possesses micromolar binding affinity but stimulates intracellular calcium mobilization at nanomolar concentrations and PGD_2 possess nanomolar binding affinity and stimulates intracellular calcium mobilization at nanomolar concentrations (Hirai et al., 2002; Hirai et al., 2001). The small

difference between the relative potencies of indomethacin and PGD₂ despite the large difference in binding affinities suggests that indomethacin may possess greater intrinsic activity, the relative ability to affect a specific conformational change in the receptor upon binding, as a CRTH2 agonist than PGD₂.

In vivo, indomethacin undergoes *O*-demethylation to yield 5'-DMI, a minor metabolite which is present in plasma and urine (Duggan et al., 1972; Vree et al., 1993). 5'-DMI has been reported to lack anti-inflammatory activity (Shen, 1964; Van Dyke et al., 1982) suggesting that it has lost the ability to inhibit cyclooxygenase. We found that 5'-DMI has similar potency to indomethacin for activating mCRTH2, initially suggesting that 5'-DMI may be a selective arylacetic acid-class CRTH2 ligand. However, further *in vitro* studies directly examining the ability of 5'-DMI to function as a COX inhibitor revealed that it is comparable to indomethacin in its ability to inhibit COX-2 and only slightly less potent for COX-1.

Several NSAIDs including indomethacin have been reported to negatively impact neutrophil function and inhibit binding of the bacterial-derived peptide f-Met-Leu-Phe (fMLP) to the surface of neutrophils (Cost et al., 1981). This is especially intriguing in light of the present studies, since the CRTH2 receptor shares significant sequence identity with the formyl peptide receptor (Nagata et al., 1999a), which is responsible for mediating the neutrophil response to the fMLP. However, whether the effects of NSAIDs on these two related receptors are due to similarities in receptor structure is unclear. The effect of NSAIDs on fMLP binding does not appear to involve competitive binding to the fMLP binding site within the formyl peptide receptor (Minta and Williams, 1985; Perianin et al., 1987), in contrast to the hypothesized interaction between indomethacin and CRTH2. This study demonstrates that the CRTH2 receptor is selective for arylacetic acid NSAIDs, whereas the inhibitory effect on fMLP binding

to neutrophils is also observed for non-arylacetic acid NSAIDs such as ibuprofen (Shelly and Hoff, 1989; Skubitz and Hammerschmidt, 1986). Furthermore, NSAID concentrations necessary to displace fMLP binding and inhibit neutrophil function are much greater than those required for the arylacetic acid NSAIDs at the CRTH2 receptor.

Previous studies have suggested that the ability of the CRTH2 receptor to be activated by indomethacin is not shared by the DP receptor (Hirai et al., 2002). However, indomethacin has been reported to bind to the human and mouse DP receptors, albeit with an order of magnitude lower affinity than CRTH2 ($K_i \approx 10 \mu\text{M}$; Hirai et al., 2003; Sawyer et al., 2002). Recently, Torisu and coworkers have reported the generation of novel indomethacin derivatives as antagonists at the mouse DP receptor. Modification of the *N*-acyl moiety and transformation of the indole-3-acetic acid template to indole-4-acetic acid gave yielded substantial increases in binding affinity and antagonistic activity (Torisu et al., 2004a). Further optimization of the *N*-acyl moiety to *N*-methyl benzomorpholine derivatives yielded potent orally active DP receptor antagonists that inhibit ovalbumin-induced vascular permeability in guinea pigs (Torisu et al., 2004b; Torisu et al., 2004c). Binding affinities for the four EP receptor isoforms and the IP receptor were also reported, but the affinity for binding CRTH2 was not discussed. Although, the DP and CRTH2 receptors possess different pharmacological profiles (Hirai et al., 2001; Sawyer et al., 2002), the observation that indomethacin and indomethacin derivatives function as CRTH2 agonists/antagonists raises the possibility that these novel DP antagonists may possess activity as agonists or antagonists at CRTH2 as well.

Acknowledgements

We thank Dr. Kevin Bacon of Bayer Yakuhin, Ltd. for providing ramatroban and Andrew Felts for providing 2-DMI. We are also grateful to Kebreab Ghebrselasie for performing cyclooxygenase assays and Eric Dawson for assistance with the molecular modeling studies.

References

- Audoly L and Breyer RM (1997) Substitution of charged amino acid residues in transmembrane regions 6 and 7 affect ligand binding and signal transduction of the prostaglandin EP3 receptor. *Mol Pharmacol* **51**:61-8.
- Barr RM, Koro O, Francis DM, Black AK, Numata T and Greaves MW (1988) The release of prostaglandin D2 from human skin in vivo and in vitro during immediate allergic reactions. *Br J Pharmacol* **94**:773-80.
- Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K₁) and the concentration of inhibitor which causes 50 per cent inhibition (I₅₀) of an enzymatic reaction. *Biochem Pharmacol* **22**:3099-108.
- Cost H, Gespach C and Abita JP (1981) Effect of indomethacin on the binding of the chemotactic peptide formyl-Met-Leu-Phe on human polymorphonuclear leukocytes. *FEBS Lett* **132**:85-8.
- DeMartino JA, Konteatis ZD, Siciliano SJ, Van Riper G, Underwood DJ, Fischer PA and Springer MS (1995) Arginine 206 of the C5a receptor is critical for ligand recognition and receptor activation by C-terminal hexapeptide analogs. *J Biol Chem* **270**:15966-9.
- Duggan DE, Hogans AF, Kwan KC and McMahon FG (1972) The metabolism of indomethacin in man. *J Pharmacol Exp Ther* **181**:563-75.
- Furse KE and Lybrand TP (2003) Three-dimensional models for beta-adrenergic receptor complexes with agonists and antagonists. *J Med Chem* **46**:4450-62.
- Goldsmith MH (1993) Cellular signaling: new insights into the action of the plant growth hormone auxin. *Proc Natl Acad Sci U S A* **90**:11442-5.

- Hamid Q, Tulic MK, Liu MC and Moqbel R (2003) Inflammatory cells in asthma: mechanisms and implications for therapy. *J Allergy Clin Immunol* **111**:S5-S12; discussion S12-7.
- Hata AN, Zent R, Breyer MD and Breyer RM (2003) Expression and Molecular Pharmacology of the Mouse CRTH2 Receptor. *J Pharmacol Exp Ther* **306**:463-470.
- Hirai H, Abe H, Tanaka K, Takatsu K, Sugamura K, Nakamura M and Nagata K (2003) Gene structure and functional properties of mouse CRTH2, a prostaglandin D(2) receptor. *Biochem Biophys Res Commun* **307**:797-802.
- Hirai H, Tanaka K, Takano S, Ichimasa M, Nakamura M and Nagata K (2002) Cutting Edge: Agonistic Effect of Indomethacin on a Prostaglandin D(2) Receptor, CRTH2. *J Immunol* **168**:981-5.
- Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, Ichimasa M, Sugamura K, Nakamura M, Takano S and Nagata K (2001) Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. *J Exp Med* **193**:255-61.
- Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP and Marnett LJ (2000a) Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. *Proc Natl Acad Sci U S A* **97**:925-30.
- Kalgutkar AS, Marnett AB, Crews BC, Remmel RP and Marnett LJ (2000b) Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. *J Med Chem* **43**:2860-70.

- Lehmann JM, Lenhard JM, Oliver BB, Ringold GM and Kliewer SA (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. *J Biol Chem* **272**:3406-10.
- Lewis RA, Soter NA, Diamond PT, Austen KF, Oates JA and Roberts LJ, 2nd (1982) Prostaglandin D₂ generation after activation of rat and human mast cells with anti-IgE. *J Immunol* **129**:1627-31.
- Lovering AL, Ride JP, Bunce CM, Desmond JC, Cummings SM and White SA (2004) Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. *Cancer Res* **64**:1802-10.
- Mills JS, Miettinen HM, Cummings D and Jesaitis AJ (2000) Characterization of the binding site on the formyl peptide receptor using three receptor mutants and analogs of Met-Leu-Phe and Met-Met-Trp-Leu-Leu. *J Biol Chem* **275**:39012-7.
- Minta JO and Williams MD (1985) Some nonsteroidal antiinflammatory drugs inhibit the generation of superoxide anions by activated polymorphs by blocking ligand-receptor interactions. *J Rheumatol* **12**:751-7.
- Murray JJ, Tonnel AB, Brash AR, Roberts LJ, 2nd, Gosset P, Workman R, Capron A and Oates JA (1986) Release of prostaglandin D₂ into human airways during acute antigen challenge. *N Engl J Med* **315**:800-4.
- Nagata K, Hirai H, Tanaka K, Ogawa K, Aso T, Sugamura K, Nakamura M and Takano S (1999a) CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). *FEBS Lett* **459**:195-9.

- Nagata K, Tanaka K, Ogawa K, Kemmotsu K, Imai T, Yoshie O, Abe H, Tada K, Nakamura M, Sugamura K and Takano S (1999b) Selective expression of a novel surface molecule by human Th2 cells in vivo. *J Immunol* **162**:1278-86.
- Narita S, Asakura K and Kataura A (1996) Effects of thromboxane A2 receptor antagonist (Bay u 3405) on nasal symptoms after antigen challenge in sensitized guinea pigs. *Int Arch Allergy Immunol* **109**:161-6.
- Negishi M, Irie A, Sugimoto Y, Namba T and Ichikawa A (1995) Selective coupling of prostaglandin E receptor EP3D to Gi and Gs through interaction of alpha-carboxylic acid of agonist and arginine residue of seventh transmembrane domain. *J Biol Chem* **270**:16122-7.
- Perianin A, Gougerot-Pocidalo MA, Giroud JP and Hakim J (1987) Diclofenac binding to human polymorphonuclear neutrophils: effect on respiratory burst and N-formylated peptide binding. *Biochem Pharmacol* **36**:2609-15.
- Prusakiewicz JJ, Felts AS, Mackenzie BS and Marnett LJ (2004) Molecular basis of the time-dependent inhibition of cyclooxygenases by indomethacin. *Biochemistry* **In press**.
- Sawyer N, Cauchon E, Chateauneuf A, Cruz RP, Nicholson DW, Metters KM, O'Neill GP and Gervais FG (2002) Molecular pharmacology of the human prostaglandin D(2) receptor, CRTH2. *Br J Pharmacol* **137**:1163-72.
- Shelly J and Hoff SF (1989) Effects of non-steroidal anti-inflammatory drugs on isolated human polymorphonuclear leukocytes (PMN): chemotaxis, superoxide production, degranulation and N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP) receptor binding. *Gen Pharmacol* **20**:329-34.

- Shen TY (1964) Synthesis and biological activity of some indomethacin analogs, in *International Symposium on Non-Steroidal Anti-Inflammatory Drugs* (Garattini S and Dukes MNG eds) pp 13-20, Excerpta Medica Foundation, Milan.
- Shichijo M, Sugimoto H, Nagao K, Inbe H, Encinas JA, Takeshita K, Bacon KB and Gantner F (2003) Chemoattractant receptor-homologous molecule expressed on Th2 cells activation in vivo increases blood leukocyte counts and its blockade abrogates 13,14-dihydro-15-keto-prostaglandin D2-induced eosinophilia in rats. *J Pharmacol Exp Ther* **307**:518-25.
- Skubitz KM and Hammerschmidt DE (1986) Effects of ibuprofen on chemotactic peptide-receptor binding and granulocyte response. *Biochem Pharmacol* **35**:3349-54.
- Stubbs VE, Schratl P, Hartnell A, Williams TJ, Peskar BA, Heinemann A and Sabroe I (2002) Indomethacin causes prostaglandin D(2)-like and eotaxin-like selective responses in eosinophils and basophils. *J Biol Chem* **277**:26012-20.
- Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M, Gantner F and Bacon KB (2003) An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. *J Pharmacol Exp Ther* **305**:347-52.
- Torisu K, Kobayashi K, Iwahashi M, Egashira H, Nakai Y, Okada Y, Nanbu F, Ohuchida S, Nakai H and Toda M (2004a) Discovery of new chemical leads for prostaglandin D(2) receptor antagonists. *Bioorg Med Chem Lett* **14**:4557-62.
- Torisu K, Kobayashi K, Iwahashi M, Nakai Y, Onoda T, Nagase T, Sugimoto I, Okada Y, Matsumoto R, Nanbu F, Ohuchida S, Nakai H and Toda M (2004b) Discovery of a new class of potent, selective, and orally active prostaglandin D(2) receptor antagonists. *Bioorg Med Chem* **12**:5361-78.

- Torisu K, Kobayashi K, Iwahashi M, Nakai Y, Onoda T, Nagase T, Sugimoto I, Okada Y, Matsumoto R, Nanbu F, Ohuchida S, Nakai H and Toda M (2004c) Discovery of orally active prostaglandin D(2) receptor antagonists. *Bioorg Med Chem Lett* **14**:4891-5.
- Van Dyke K, Peden D, Van Dyke C, Jones G, Castranova V and Ma J (1982) Inhibition by nonsteroidal antiinflammatory drugs of luminol-dependent human-granulocyte chemiluminescence and [3H]FMLP binding. Effect of sulindac sulfide, indomethacin metabolite, and optical enantiomers (+) and (-) MK830. *Inflammation* **6**:113-25.
- Vree TB, van den Biggelaar-Martea M and Verwey-van Wissen CP (1993) Determination of indomethacin, its metabolites and their glucuronides in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis. Preliminary pharmacokinetics and effect of probenecid. *J Chromatogr* **616**:271-82.
- Zhang X, Morham SG, Langenbach R and Young DA (1999) Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. *J Exp Med* **190**:451-59.

Footnotes

This work was supported by grants from the National Institutes of Health GM15431 (R.M.B. and L.J.M.), DK46205 (R.M.B.), NS33290 (T.P.L.) as well as the Vanderbilt-Ingram Cancer Center. A.N.H. is supported by a PhRMA Foundation predoctoral fellowship.

Reprint requests:

Richard M. Breyer, Vanderbilt University School of Medicine, Division of Nephrology, S3223 MCN, 1161 21st Ave South, Nashville, TN 37232-2372

Legends for Figures

Figure 1

Competition binding analysis of arylacetic acid NSAIDs. Membranes isolated from HEK293 cells transiently transfected with mCRTH2 were incubated with 1 nM [³H]PGD₂ in the presence of varying concentrations of indomethacin (squares), zomepirac (circles), sulindac sulfide (triangles) or diclofenac (diamond) as described under *Materials and Methods*. Binding curves were generated using a one-site competition model. Each data point was determined in triplicate; error bars represent S.E.M. These data are representative of three independent experiments.

Figure 2

Structures of arylacetic acid NSAIDs, indole and indomethacin derivatives tested in these studies.

Figure 3

Competition binding analysis of indole and indomethacin derivatives. Membranes isolated from HEK293 cells transiently transfected with mCRTH2 were incubated with 1 nM [³H]PGD₂ in the absence or presence of (A) 30 μM of indole derivative, (B) varying concentrations of indomethacin (squares), 5'-DMI (circles), PBI (triangles) or 2-DMI (diamonds), or (C) 30 μM of neutral indomethacin derivative as described under *Materials and Methods*. Binding curves (B) were generated using a one-site competition model. Each data point was determined in

triplicate; error bars represent S.E.M. These data are representative of 3 independent experiments.

Figure 4

mCRTH2-evoked inhibition of FSK-stimulated $[cAMP]_i$ by arylacetic acid NSAIDs and indomethacin derivatives. ER293/mCRTH2 cells were stimulated with 10 μ M forskolin in the absence (control) or presence of NSAIDs or indomethacin derivatives for 10 minutes and $[cAMP]_i$ levels were determined as described under *Materials and Methods*. A, NSAIDs (1 μ M) exhibit differing potencies for inhibiting $[cAMP]_i$; indomethacin maximally inhibits $[cAMP]_i$ to a similar degree as the endogenous ligand PGD_2 (100 nM). B, 5'-DMI (circles) exhibits similar potency to indomethacin (squares) for inhibiting $[cAMP]_i$, whereas 2-DMI (diamonds) was 10-fold less potent. C, Zomepirac does not inhibit $[cAMP]_i$ at concentrations up to 50 μ M. D, Zomepirac is a weak antagonist of mCRTH2-evoked inhibition of $[cAMP]_i$ by indomethacin. ER293/mCRTH2 cells were incubated with varying concentrations of zomepirac in the presence of 0.01 μ M indomethacin. The ability of 1 μ M ramatroban, a known CRTH2 antagonist, to reverse the inhibition of $[cAMP]_i$ by indomethacin is shown for comparison. For A, C and D, each data point was determined in triplicate and the mean value from 3-8 independent experiments is shown (error bars represent S.E.M.). For B, each data point was determined in duplicate; data are representative of 3 independent experiments. *, $p < 0.05$ compared with control (FSK-stimulated in absence of ligand).

Figure 5

Arylacetic acid NSAIDs and indomethacin derivatives stimulate chemotaxis of ER293/mCRTH2 cells. Migration of ER293/mCRTH2 (solid bars) or vector control ER293/pEGSH cells (open bars) in response to PGD₂, arylacetic acid NSAIDs and indomethacin derivatives (100 nM) was assessed as described in *Materials and Methods*. Data are expressed as percentage of cells migrating in the absence of added ligand (control). The average number of migrated cells from 5 high-power fields was determined for each experimental condition, and the mean value from 3-5 independent experiments is shown; error bars represent S.E.M. *, $p < 0.05$ compared with vector-transfected cells.

Figure 6

Molecular modeling of mCRTH2-indomethacin complexes. A, Side (left) and extracellular (right) views of indomethacin (red spheres) docked in the putative ligand binding pocket of mCRTH2. B, The acetic acid carboxylate of indomethacin (red) forms a charge stabilized hydrogen bond with K209 (red) of helix V (inset, close-up view showing position of the K209 hydrogen participating the in hydrogen bond). C, The position of the *p*-chlorobenzyl moiety of indomethacin (red) suggests a hydrophobic stacking interaction with the aromatic ring of F110 (blue) of helix III.

Figure 1

Molecular Pharmacology Fast Forward. Published on November 24, 2004 as DOI: 10.1124/mol.104.007971
This article has not been copyedited and formatted. The final version may differ from this version.







Figure 2




Indomethacin




Sulindac sulfide




Zomepirac




Diclofenac




Ramatroban




Indole




Indole-3-acetic acid (IAA)




Tryptophan




5-hydroxytryptophan




Serotonin




5-HIAA




5'-O-desmethyl indomethacin (5'-DMI)




2-desmethyl indomethacin (2-DMI)



p-bromo-benzyl indomethacin (PBI)



Indomethacin methyl ester






Indomethacin amide

Molecular Pharmacology Fast Forward. Published on November 24, 2004 as DOI: 10.1124/mol.104.007971
This article has not been copyedited and formatted. The final version may differ from this version.

Downloaded from molpharm.physocpubs.org at ASPET Journals on April 20, 2014

Figure 3



Molecular Pharmacology Fast Forward. Published November 20, 2024. DOI: 10.1124/mp.12007971
This article has not been certified for peer review. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 20, 2024

Figure 4







Figure 5



A**B****C**